Always glad to admit my suspicions were wrong - based on @CIBMTR data, no reason to doubt ide-cel CAR-T’s efficacy in #MMsm based on presence vs absence of prior transplant. Now in @BloodPortfolio - by @drjgauthier @emilyliangmd @MadhavDhodapkar @AJPortuguese @fredhutch et al!

My wish is coming true @ASH_hematology @Mohty_EBMT @TheEBMT_CTIWP late breaking abstract👇congrats 👏👏to Austarian Myeloma Team Drs Ho & Spencer

Holy moly est 36-month PFS is over 80%!

They developed, to their knowledge, the first pooled CAR-T screening platform in an immunocompetent NHP model to directly compare CAR designs. Read in Blood: https://t.co/aToeJXmyEu

Comparison of Standard of Care with or Without a PD-1/PD-L-1 Inhibitor for the Treatment of Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials #mmsm #myeloma #MedEd #MedTwitter @USMIRCNEWS #USMIRC @OncoAlert @US_HMC

Patient perspectives & preferences for step-up dosing and treatment w/ teclistamab & talquetamab: Insights from a patient survey [Nov 3, 2025] @JayHydren et al. @RahulBanerjeeMD abs25-8335 PID 6354 https://t.co/pRlflaSISg #mmsm #Tcellrx @HealthTree

Initial phase 1b/2 study results w/ sonrotoclax (BGB-11417) in combination w/ carfilzomib + dex [Kd] in Pts w/ t(11;14)-positive RRMM [Nov 3, 2025] @HangQuach1 et al. #ASH25 abs25-7278 PID 102 https://t.co/ynTVsfNIR6 #mmsm #PrecisionMedicine n=20. ORR 84% HT @End_myeloma

In a real-world setting, #CAR T-cell therapies including axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel demonstrate superior survival outcomes compared to traditional salvage therapy for patients with #FL. Learn more: https://t.co/ss4FFKDihr

BCMA: BeCoMing a new hope for AL amyloidosis #mmsm #amyloidosis @BloodPortfolio https://t.co/xiLhmNB0d0

Check our work: Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort @BrJHaem #mmsm , now available on PubMed ➡️ https://t.co/cwNggtSmB8 @MansiShahMD @MeeraMohanMD

Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study @BloodCancerJnl #mmsm In our real world analysis of Talquetamab, infections with Talquetamab were less common when compared to Teclistimab with more viral infections than bacterial

For patients with myeloma #MMsm and no response after 1 month of bispecific antibodies, should therapy be continued or changed? More by @RahulBanerjeeMD et al out now in @AjHematology. https://t.co/aV2rpKDtgI @AlGarfall

Strong showing for ⁦@TischCancer⁩ ⁦@IcahnMountSinai⁩ at the ⁦@Myeloma_Society⁩ meeting in Amsterdam. #mmsm

They say “act like you’ve been there “. But I’ll never get over the excitement of being In a room / on stage with the world’s leaders in myeloma. The group in this room today will be part of the cures of the future ! #mmsm ⁦@Myeloma_Society⁩

Samir Parekh giving a powerful talk on the role of the immune micro environment in smoldering myeloma #mmsm ⁦@Myeloma_Society⁩ ⁦@TischCancer⁩

Letting the imposter syndrome continue to wash over me ☺️. En route to Amsterdam to hobnob with the myeloma elite to discuss smoldering myeloma. Trying to win the war before it starts ! ⁦@Myeloma_Society⁩ ⁦@VincentRK⁩ #mmsm

Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression https://t.co/uWcef4cDLY @alagana1 and colleagues @IcahnMountSinai #MultipleMyeloma

As a doctor, you can get pulled in many directions, face all kinds of obstacles, and encounter relentless clerical duties and paperwork that seems unending. Ultimately whether it’s practice or research, one patient in our office, or a patient far away through our research.

People often don’t advertise their obstacles and failures…. But these are also the realities of life. An inspiring story from @DrKrinaPatel on how she navigated the difficulties of an academic career from the start… to now being the Chief of Myeloma at @MDAndersonNews 🙌🏼

Nice work (and visual abstract!) @BrJHaem by Seefat #nielsvandedonk @SonjaZweegman et al. PK & PD with ∆ pom dosing in myeloma #MMsm. Pom 2mg QD = pom 4mg QD in terms of Ikaros/Aiolos knockdown. Pom Q2D not as effective here. Pom 2mg 21/28 days my go-to for many, e.g. KPd!